BioNTech SE licences Cresendo Bios Humab...BioNTech and Crescendo Biologics have signed a US-$790m deal to develop multi-specific precision immunotherapies . more ➔
Novartis AG executes licence option with M...After Molecular Partners AG reported an 78% reduction of hospitalisation by a single ensovibep dose in infected COVID-19 patients, Novartis AG is to pay a CHF150m milestone. more ➔
Neurimmune inks US-$760 deal with AstraZen...Neurimmune has entered into a collaboration and license agreement with AstraZeneca subsidiary Alexion Pharmaceuticals to commercialise its antibody NI006. more ➔
Santhera finds Chinese marketing partner f...Swiss Santhera Pharmaceuticals has entered into a $124m licence deal with Chinese Sperogenix Therapeuticis to market its DMD drug vamorolone. more ➔
DNA Script bags US$200m financingModerna’s US-French partner DNA Script has raised additional $35m as a second tranche of a Series C financing to advance its Enzymatic DNA Synthesis platform, Syntax. more ➔
Sound Bioventures Fund I AB closes at €1...Novo Holdings, together with Saminvest, Vækstfonden, the European Investment Fund and its three co-founders have put €110m in the first fund of Sound Bioventures AB. more ➔
Novo Holdings invests €86m in 21st.BIONovo Holdings is set to invest €86m in 21st.BIO A/S – a new Danish bioindustrial scale-up company – to boost the production of proteins. more ➔
Novartis AG snags Gyroscope for US$1.5bnOcular gene therapy specialist Gyroscope Therapeutics Holdings plc is to be acquired by Novartis AG for up to $1.5bn. more ➔
NorthSea Therapeutics completes US$80m Ser...Dutch metabolic disease specialist NorthSea Therapeutics NV has baged US$80m in a Series C fundraising co-led by Ysios Capital and Forbion Growth. more ➔
